Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
6
×
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
6
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
gilead sciences
biogen
cancer immunotherapy
clinical trials
deals
gene therapy
glaxosmithkline
startups
alzheimer's disease
amgen
astrazeneca
What
bio
roundup
6
×
acquisitions
ceo
drug
biggest
daniel
days
gilead
news
o’day
sciences
abbvie’s
ahead
albert
announced
approval
august
biofourmis
biogen’s
biopharmaceutical
biotech
bourla
bucks
build
busy
buy
cancer
celebrate
chance
collabs
companies
company
company’s
convo
corner
covid
crispr
day
deal
Language
unset
unknown
Current search:
biotech
×
novartis
×
abbvie
×
roundup
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More